Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Revenue

Tibet Rhodiola Pharmaceutical Holding Co. had revenue of 712.11M CNY in the quarter ending March 31, 2025, with 1.12% growth. This brings the company's revenue in the last twelve months to 2.81B, down -3.99% year-over-year. In the year 2024, Tibet Rhodiola Pharmaceutical Holding Co. had annual revenue of 2.81B, down -10.45%.

• Revenue (ttm): 2.81B
• Revenue Growth: -3.99%
• P/S Ratio: 4.22
• Revenue / Employee: 4.72M
• Employees: 596
• Market Cap: 11.87B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.81B	-327.62M	-10.45%
Dec 31, 2023	3.13B	579.72M	22.69%
Dec 31, 2022	2.55B	416.02M	19.45%
Dec 31, 2021	2.14B	765.48M	55.75%
Dec 31, 2020	1.37B	117.08M	9.32%